Alerta

DIAGNOSTIC ASSAYS AND METHODS FOR DETECTING PATHOGENS

Resumen de: US20260242880A1

Provided are methods for co-extraction of DNA or RNA from two or more pathogens (such as Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (SC2)) in a sample. Also provided are assays for identifying a pathogen (such as Tuberculosis (TB)) directly from a sample.

COMPOSITION FOR PREVENTING OR TREATING CHEMOSENSORY DISORDER

Resumen de: US20260240922A1

0000 The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, comprising a lactic acid bacterium. The chemosensory disorder can be a chemosensory disorder that occurs after SARS-CoV-2 viral infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect against a chemosensory disorder, and a pharmaceutical product or a food product that is safe for mammals including humans can be provided.

METHYLATION SIGNATURES OF PATHOGEN AND CHEMICAL EXPOSURES IN HUMAN CELLS

Resumen de: US20260242881A1

0000 Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.

Core amino acid sequence group for targeted recognition of anti-SARS-Cov-2 neutralizing antibodies N-lgY-pAbs, and use thereof

Resumen de: AU2026210797A1

WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies 5 N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, and the designing of treatment targets and designing of vaccine targets. In the above amino acid sequence group, it is found that P272 in only one aa261-275 sequence of an S protein is a residue with a low-frequency mutation, and the remaining 19 sequences are 10 conservative amino acid sequences, do not contain the currently discovered virus mutation sites, and are highly conservative, which can effectively cope with the unfavorable situation of high-frequency mutation of SARS-CoV-2 at present. WZF000PTEA01D2300070 Specifically disclosed are a core amino acid sequence group for the targeted recognition of anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs, and the use thereof. The core amino acid 5 sequence group for the targeted recognition of the anti-SARS-CoV-2 neutralizing antibodies N-IgY-pAbs comprises 15 amino acid sequences located in an S-ECD domain and 5 amino acid sequences located in a non-structural protein (NSP) domain, and can be applied to the detection of SARS-CoV-2, a

ANTIMICROBIAL AND ANTIVIRAL, BIOLOGICALLY ACTIVE POLYMER COMPOSITES EFFECTIVE AGAINST SARS-COV-2 AND OTHER VIRAL, BACTERIAL AND FUNGAL TARGETS, AND RELATED METHODS, MATERIALS, COATINGS AND DEVICES

Resumen de: US20260240166A1

0000 Biologically active ion-exchange polymer salts are made by exchanging biologically active ionic agents onto organic ion exchange polymers. The activated polymers are uniquely surface active for use in a wide range of antibacterial, antifungal and antiviral coatings, materials, and devices, to minimize or prevent pathogen transmission and/or infection of a susceptible individual such as a patient in a hospital. The resultant coatings, materials, and devices are the foundation of a system enabling the construction of spheres of protection, for example to protect against transmission of COVID-19 (SARS-COV-2) coronaviruses and other viral and fungal pathogens in a clinical or institutional environment, for example hospitals, community institutions, cruise ships, and long-term care facilities. The activated ion-exchange polymer salts are process stable, allowing size reduction and formulation of the resulting powders into bulk polymers or polymer precursors to produce stable, biologically active polymer composites, including antimicrobial and antiviral polymer composites.

LUMINOL FOR THE PROPHYLAXIS AND THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION

Resumen de: WO2022117221A1

The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.

Improved form of a liposomal trap inhibitor of SARS-CoV-2 infection

Nº publicación: PL451191A1 17/08/2026

Solicitante:

ACELLMED SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA [PL]
ACELLMED SP\u00D3\u0141KA Z OGRANICZON\u0104 ODPOWIEDZIALNO\u015ACI\u0104

Resumen de: PL451191A1

Przedmiotem zgłoszenia jest liposomowy preparat, do stosowania w leczeniu COVID-19.